| Original language | English |
|---|---|
| Pages (from-to) | 1087-1088 |
| Number of pages | 2 |
| Journal | Progress in Neuro-Psychopharmacology and Biological Psychiatry |
| Volume | 32 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 2008 May 15 |
ASJC Scopus subject areas
- Pharmacology
- Biological Psychiatry
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
A case of transient hallucination with ropinirole augmentation antidepressant in a patient with treatment-resistant depression : Is there differential effect of ropinirole dose on developing psychotic symptom? / Pae, Chi Un; Marks, David M.; Han, Changsu; Patkar, Ashwin A.
In: Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 32, No. 4, 15.05.2008, p. 1087-1088.Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - A case of transient hallucination with ropinirole augmentation antidepressant in a patient with treatment-resistant depression
T2 - Is there differential effect of ropinirole dose on developing psychotic symptom?
AU - Pae, Chi Un
AU - Marks, David M.
AU - Han, Changsu
AU - Patkar, Ashwin A.
N1 - Funding Information: Dr. Pae has received research grant from GlaxoSmithKline Korea, GlaxoSmithKline, AstraZeneca Korea, Jansssen Pharmaceutcals Korea, Eli Lilly and Company Korea, Korean Research Foundation, Otsuka Korea, Wyeth Korea, and Korean Institute of Science and Technology Evaluation and Planning; has received honoraria and is on the speaker's bureaus of GlaxoSmithKline Korea, Lundbeck Korea, AstraZeneca Korea, Jansssen Pharmaceutcals Korea, Eli Lilly and Company Korea, McNeil Consumer and Specialty Inc, and Otsuka Korea. Dr. Han has received research support from Korea Research Foundation Grant (MOEHRD) (KRF-2007-013-E00033) and from Korea University Neuropsychiatric Alumni Grant. Dr. Marks has no financial disclosures. Dr. Patkar is a consultant for Bristol-Myers Squibb, GlaxoSmithKline, and Reckitt Benckiser; is on the speaker's bureau of Bristol-Myers Squibb, GlaxoSmithKline, and Reckitt Benckiser; has received research support from National Institutes of Health, AstraZeneca, Bristol-Myers Squibb, Forest, GlaxoSmithKline, Janssen, McNeil Consumer and Specialty Inc, Organon, Jazz Pharmaceuticals, and Pfizer. Copyright: Copyright 2008 Elsevier B.V., All rights reserved.
PY - 2008/5/15
Y1 - 2008/5/15
UR - http://www.scopus.com/inward/record.url?scp=42949126634&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=42949126634&partnerID=8YFLogxK
U2 - 10.1016/j.pnpbp.2008.02.011
DO - 10.1016/j.pnpbp.2008.02.011
M3 - Letter
C2 - 18384925
AN - SCOPUS:42949126634
VL - 32
SP - 1087
EP - 1088
JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry
JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry
SN - 0278-5846
IS - 4
ER -